[Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin therapy].
Bacillus Calmette-Guérin (BCG) immunotherapy is increasingly being accepted for management of some bladder transitional cell neoplastic lesions. Mild adverse reactions occur frequently. However, an unusual complication of tuberculous epididymitis is reported. A 64-year old man presented with bilateral epididymal mass. Four months earlier he had seven treatments with intravesical BCG instillation (Tokyo 172 strain) for a grade 2 transitional cell carcinoma in situ. Bilateral epididymectomy was performed. Microscopic examination of the epididymis revealed chronic inflammation and necrosis with granulomas and Langhans' giant cells. After the operation, there were no further complications.
Okadome
Aya
A
Department of Urology, Chikushi Hospital, Fukuoka University, Chikushino, Japan.
Takeuchi
Fumio
F
Ishii
Tatsu
T
Hiratsuka
Yoshiharu
Y
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000009:adverse effects*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D004823:Epididymitis / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014389:Tuberculosis, Male Genital / Q000209:etiology*; D014523:Urethral Neoplasms / Q000188:drug therapy
D001500:BCG Vaccine